EXIMIAS PHARMACEUTICAL CORPORATION
Eximias Pharmaceutical Corporation is a healthcare and pharmaceutical company. It focuses on the acquisition, development, and commercialization of unique oncology and infectious disease products. The company has three novel, late-stage products, THYMITAQ(R) and ORATAQ(TM) for oncology, and MACROTAC(TM) for oncology and infectious disease. THYMITAQ(R), the company's flagship product, is being evaluated in a Phase III ETHECC(C) trial for the treatment of patients with unresectable liver cancer. Eximias Pharmaceutical Corporation was founded in 1997. The company was founded by YM BioSciences on April 1, 2006.
EXIMIAS PHARMACEUTICAL CORPORATION
Industry:
Biotechnology Health Care Medical
Founded:
1997-01-01
Address:
Berwyn, Pennsylvania, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
0
Current Employees Featured
Investors List
Birchmere Ventures
Birchmere Ventures investment in Seed Round - Eximias Pharmaceutical Corporation